Prevalence and incidence of sexually transmitted infections among South African women initiating injectable and long-acting contraceptives

Show simple item record

dc.contributor.author Harryparsad, Rushil
dc.contributor.author Meyer, Bahiah
dc.contributor.author Taku, Ongeziwe
dc.contributor.author Serrano, Myrna
dc.contributor.author Chen, Pai Lien
dc.contributor.author Gao, Xiaoming
dc.contributor.author Williamson, Anna-Lise
dc.contributor.author Mehou-Loko, Celia
dc.contributor.author D’Hellencourt, Florence Lefebvre
dc.contributor.author Smit, Jennifer
dc.contributor.author Strauss, Jerome
dc.contributor.author Nanda, Kavita
dc.contributor.author Ahmed, Khatija
dc.contributor.author Beksinska, Mags
dc.contributor.author Buck, Gregory
dc.contributor.author Morrison, Charles
dc.contributor.author Deese, Jennifer
dc.contributor.author Masson, Lindi
dc.date.accessioned 2024-11-04T11:16:13Z
dc.date.available 2024-11-04T11:16:13Z
dc.date.issued 2023-11-10
dc.description DATA AVAILABILITY STATEMENT : The data that support the findings of this study are available in Table S5. en_US
dc.description SUPPORTING INFORMATION : QUESTIONNAIRE S1. Inclusivity in global research. FIGURE S1. Total proportion of women with active sexually transmitted infections (STIs) at baseline by study site. The Setshaba (n = 53) study site had a greater proportion of Trichomonas vaginalis (TV) and multiple STI infections compared to the MatCH (n = 109) study site. FIGURE S2. (A-C). Kaplan-Meier curve showing sexually transmitted infection (STI) incidence between study site by age group over time (days). Red represents the MatCH site, green the Setshaba site. The tables show the number of individuals at risk of acquiring STIs over time. A vertical drop represents an event has occurred and a verticle tick mark on the curves indicate that a participant has been censored at that timepoint. (A), STI incidence between sites for 18– 21 year olds were not statistically significant. (B), There was no statistically significant differences for 25–33 years olds between sites. (C), STI incidence between sites for 26–33 year olds had a statistically significant difference (p = 0.002). FIGURE S3. Kaplan-Meier curve showing any active sexually transmitted infection (STI) incidence between participants testing positive or negative for vaginal prostate specific antigen (PSA). Red represents participants positive for PSA at any visit, green indicates participants negative for PSA at all visits. The tables show the number of individuals at risk of acquiring any active STI over time. A vertical drop represents an event has occurred and a cross mark on the curves indicates that a participant has been censored at that timepoint. There was no statistically significant difference in the incidence of an active STI between participants positive or negative for PSA. FIGURE S4. Total proportion of women reporting ever using condoms according to prostate specific antigen (PSA) detection at baseline. There were no significant differences in PSA detection in women who reported condom use and in women reporting no condom usage. FIGURE S5. Vaginal prostate specific antigen (PSA) concentrations according to reported time since last vaginal intercourse (days). PSA concentration was significantly higher among women reporting vaginal intercourse 0–4 days compared to 8–13 days prior to the study visit (p = 0.03). TABLE S1. Baseline demographic, behavioural and clinical characteristics of study by study site. Abbreviations: ¥ n = 107;kg, kilogram; cm, centimeter. Proportions were compared using the Chi-Square test and continuous variables were compared using Kruskal-Wallis test. *p<0.05 following Bonferroni correction was considered statistically significant. TABLE S2. Baseline STI prevalence overall and by study site. Abbreviations: STI, sexually transmitted infection. ^tested positive for at least one STI (CT, NG, TV, MG or HSV-2). Proportions were compared using the Fishers Exact test *p<0.05 TABLE S3. Baseline STI prevalence overall and by contraceptive group. Abbreviations: STI, sexually transmitted infection. ^tested positive for at least one STI (CT, NG, TV, MG or HSV- 2). Proportions were compared using the Fishers Exact test *p<0.05 following Bonferroni correction was considered statistically significant. TABLE S4. Three-month STI incidence overall and by study site. *p<0.05 following Bonferroni correction was considered statistically significant. TABLE S5. Full study dataset. en_US
dc.description.abstract BACKGROUND : South Africa is among the countries with the highest prevalence of sexually transmitted infections (STIs), including Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). In 2017, there were an estimated 6 million new CT, 4.5 million NG and 71 000 Treponema pallidum infections among South African men and women of reproductive age. METHODS : We evaluated STI prevalence and incidence and associated risk factors in 162 women aged 18–33 years old, residing in eThekwini and Tshwane, South Africa who were part of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial. Women were randomised to use depot medroxyprogesterone acetate (n = 53), copper intrauterine device (n = 51), or levonorgestrel (n = 58) implant. Lateral vaginal wall swab samples were collected prior to contraceptive initiation and at months one and three following contraceptive initiation for STI testing. RESULTS : There were no significant differences in STI incidence and prevalence across contraceptive groups. At baseline, 40% had active STIs (CT, NG, Trichomonas vaginalis (TV), Mycoplasma genitalium (MG) or herpes simplex virus-2 shedding across all age groups– 18–21 years (46%), 22–25 years (42%) and 26–33 years (29%). The incidence of STIs during follow-up was exceptionally high (107.9/100 women-years [wy]), with younger women (18–21 years) more likely to acquire CT (75.9/100 wy) compared to 26–33 year olds (17.4/ 100 wy; p = 0.049). TV incidence was higher in the 26–33 year old group (82.7/100 wy) compared to the 18–21 year olds (8.4/100 wy; p = 0.01). CONCLUSIONS : Although the study participants received extensive counselling on the importance of condom use, this study highlights the high prevalence and incidence of STIs in South African women, especially amongst young women, emphasising the need for better STI screening and management strategies. en_US
dc.description.department Medical Microbiology en_US
dc.description.librarian am2024 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship The Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institute of Health, the Carnegie Corporation of New York, South African National Research Foundation and Australian National Health and Medical Research Council. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial was supported by the combined generous support of the Bill & Melinda Gates Foundation; the American people through the United States Agency for International Development, the Swedish International Development Cooperation Agency; the South Africa Medical Research Council; and the United Nations Population Fund. Contraceptive supplies were donated by the Government of South Africa and US Agency for International Development. en_US
dc.description.uri https://journals.plos.org/plosone/ en_US
dc.identifier.citation Harryparsad R, Meyer B, Taku O, Serrano M, Chen PL, Gao X, et al. (2023) Prevalence and incidence of sexually transmitted infections among South African women initiating injectable and longacting contraceptives. PLoS One 18(11): e0294285. https://DOI.org/10.1371/journal.pone.0294285. en_US
dc.identifier.issn 1932-6203
dc.identifier.other 10.1371/journal.pone.0294285
dc.identifier.uri http://hdl.handle.net/2263/98911
dc.language.iso en en_US
dc.publisher Public Library of Science en_US
dc.rights © 2023 Harryparsad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License. en_US
dc.subject Counselling en_US
dc.subject Condom use en_US
dc.subject Women en_US
dc.subject Sexually transmitted infection (STI) en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Prevalence and incidence of sexually transmitted infections among South African women initiating injectable and long-acting contraceptives en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record